Tenders Are Invited For Pharmaceutical Products - Conclusion Not Excluding Drug Discount Agreement. Accordin ...

Work Detail

Pharmaceutical Products - Conclusion Not Excluding Drug Discount Agreement. According To Section 130A Paragraph 8 Sgb V Through An Open House Model For The Active Ingredient Glatiramer Acetate (Atc Code According To Who: L03ax13). The Subject Of This Publication Is The Conclusion Of Non-Exclusive Discount Agreements According To Section 130A Paragraph 8 Sgb V On Medicines With The Active Ingredient Glatiramer Acetate (Atc Code According To Who: L03ax13). The Contract Is Concluded Within The Framework Of A So-Called Open House Model, D. H. Anyone Interested Can Sign A Contract Within The Participation Period Open To Pharmaceutical Companies As Long As They Meet The Participation Requirements And Accept. This Means That Individual Contract Negotiations Are Not Possible And There Is No (Delivery) Exclusivity. It Is Pointed Out That That The Purchase Quantity Is Unknown As It Depends On Demand And Development The Number Of Insured People, The Prescribing Behavior Of Doctors As Well As The Dispensing And The Stocking Behavior Of Public Pharmacies Depends. Minimum Purchase Quantities Are Therefore Not Guaranteed. Interested Pharmaceutical Entrepreneurs Participation Documents Can Be Submitted Via The Project Room Of The German Procurement Portal (Dtvp). Download. To Do This, You Must First Submit An Application For Access To The Project Room. After Activation By The Client, You Can Then Access The Participation Documents Can Be Accessed. The Documents To Be Submitted Are Based On Those In The Project Room Deposited Documents “Cover Letter” And “Explanations Of The Contractual Conditions”. Communication, Including The Transmission Of Participation Documents, Takes Place Electronically Via The Dtvp Procurement Portal; Details On This Are As Mentioned Above Documents. Any Other Information In The Contract Notice Are Due To Technical Reasons And Are Not Binding. Requests To Participate Can Be Submitted For The First Time By January 5Th, 2024. All Other Submission Deadlines Please Refer To The “Submission Deadlines” Appendix In The Project Room. If The Day Of The Submission Deadline Falls On A Saturday, Sunday Or A Federal Legal Date Public Holiday, Such A Day Is Replaced By The Next Working Day. In Case Of Delay Once Received, The Submitted Applications For Participation Will Be Considered For The Next Submission Deadline. The Client Reserves The Right To Ensure Compliance With The Pharmaceutical Company Of The Principles Of Transparency And Equal Treatment, To Call For Missing, Incomplete Ones Or To Submit Incorrect Documents (In Particular Explanations, Information And Evidence), To Complete Or Correct (Additional Request). The Documents Are From The Pharmaceutical Company Entrepreneurs Upon Request By The Client Within A Period Of Time According To The Calendar To Be Submitted Within A Certain Deadline. If The Requested Documents Are Not Received Within Submitted Before The Deadline, The Application For Participation Can Be Excluded Or Postponed Until The Next One Submission Deadline Will Be Taken Into Account. The Discount Agreement Ends, Regardless From The Date Of Conclusion Of The Contract, No Later Than January 31, 2025. The Client Retains Reserves The Right To End The Open House Procedure Early, Especially In The Event Of Conclusion Of Exclusive Discount Agreements; In This Case, Those Already Closed Will End Discount Agreements In Accordance With The Contractual Provisions. The Experiences According To The Client, Exclusive Discount Agreements Usually Come Into Effect Between 8 And 12 Months After The Publication Of The Relevant Contract Notice In The Supplement To The Official Journal Of The European Union.

Contact Information

Other Detail